nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—embryo—testicular cancer	0.0187	0.149	CbGeAlD
Pimecrolimus—MTOR—seminal vesicle—testicular cancer	0.0176	0.14	CbGeAlD
Pimecrolimus—FKBP1A—seminal vesicle—testicular cancer	0.0158	0.126	CbGeAlD
Pimecrolimus—MTOR—gonad—testicular cancer	0.0127	0.101	CbGeAlD
Pimecrolimus—FKBP1A—gonad—testicular cancer	0.0114	0.0908	CbGeAlD
Pimecrolimus—MTOR—female gonad—testicular cancer	0.0103	0.082	CbGeAlD
Pimecrolimus—FKBP1A—female gonad—testicular cancer	0.00928	0.0738	CbGeAlD
Pimecrolimus—MTOR—testis—testicular cancer	0.00915	0.0728	CbGeAlD
Pimecrolimus—MTOR—mTOR signalling—STK11—testicular cancer	0.00896	0.0406	CbGpPWpGaD
Pimecrolimus—MTOR—PKB-mediated events—STK11—testicular cancer	0.0087	0.0394	CbGpPWpGaD
Pimecrolimus—FKBP1A—testis—testicular cancer	0.00823	0.0654	CbGeAlD
Pimecrolimus—MTOR—lymph node—testicular cancer	0.00664	0.0527	CbGeAlD
Pimecrolimus—MTOR—LKB1 signaling events—STK11—testicular cancer	0.00617	0.028	CbGpPWpGaD
Pimecrolimus—FKBP1A—lymph node—testicular cancer	0.00597	0.0474	CbGeAlD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00458	0.0208	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K Cascade—STK11—testicular cancer	0.00428	0.0194	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—STK11—testicular cancer	0.00423	0.0192	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—STK11—testicular cancer	0.00358	0.0162	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—STK11—testicular cancer	0.00348	0.0158	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00345	0.0156	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—STK11—testicular cancer	0.00336	0.0152	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—STK11—testicular cancer	0.00336	0.0152	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00333	0.0151	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.00328	0.0149	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.0032	0.0145	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00305	0.0138	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—KITLG—testicular cancer	0.00296	0.0134	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K Cascade—FGFR3—testicular cancer	0.00294	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—KITLG—testicular cancer	0.00288	0.0131	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—KITLG—testicular cancer	0.00286	0.013	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—BCL10—testicular cancer	0.00283	0.0128	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.0028	0.0127	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—STK11—testicular cancer	0.00279	0.0126	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—FGFR3—testicular cancer	0.00246	0.0111	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00244	0.011	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—FGFR3—testicular cancer	0.00239	0.0108	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.00237	0.0107	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—FGFR3—testicular cancer	0.00231	0.0105	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.00231	0.0105	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.00226	0.0102	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.00224	0.0101	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KITLG—testicular cancer	0.00221	0.01	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—FGFR3—testicular cancer	0.0022	0.00995	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—FGFR3—testicular cancer	0.00214	0.00971	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—FGFR3—testicular cancer	0.00213	0.00963	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00211	0.00957	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KITLG—testicular cancer	0.00208	0.00942	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00208	0.00941	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—KIT—testicular cancer	0.00202	0.00913	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KITLG—testicular cancer	0.00199	0.009	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KITLG—testicular cancer	0.00198	0.00895	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—KIT—testicular cancer	0.00197	0.00891	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KITLG—testicular cancer	0.00197	0.00891	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KITLG—testicular cancer	0.00196	0.00887	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—KIT—testicular cancer	0.00195	0.00884	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00193	0.00874	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—FGFR3—testicular cancer	0.00192	0.00869	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.00191	0.00864	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00184	0.00834	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KITLG—testicular cancer	0.00184	0.00834	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KITLG—testicular cancer	0.00184	0.00834	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KITLG—testicular cancer	0.00183	0.00827	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.00181	0.00819	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KITLG—testicular cancer	0.0018	0.00816	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KITLG—testicular cancer	0.0017	0.00772	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—FGFR3—testicular cancer	0.00164	0.00744	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Vinblastine—testicular cancer	0.00164	0.00251	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Cisplatin—testicular cancer	0.00164	0.00251	CcSEcCtD
Pimecrolimus—Oedema—Dactinomycin—testicular cancer	0.00163	0.0025	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00163	0.00739	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—INSL3—testicular cancer	0.00163	0.00737	CbGpPWpGaD
Pimecrolimus—Infection—Dactinomycin—testicular cancer	0.00162	0.00248	CcSEcCtD
Pimecrolimus—Pruritus—Chlorambucil—testicular cancer	0.0016	0.00245	CcSEcCtD
Pimecrolimus—Cough—Ifosfamide—testicular cancer	0.0016	0.00245	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.0016	0.00244	CcSEcCtD
Pimecrolimus—Erythema—Cisplatin—testicular cancer	0.00158	0.00242	CcSEcCtD
Pimecrolimus—Malnutrition—Cisplatin—testicular cancer	0.00158	0.00242	CcSEcCtD
Pimecrolimus—Paraesthesia—Bleomycin—testicular cancer	0.00157	0.00241	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00157	0.00711	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Bleomycin—testicular cancer	0.00156	0.00239	CcSEcCtD
Pimecrolimus—Arthralgia—Ifosfamide—testicular cancer	0.00156	0.00239	CcSEcCtD
Pimecrolimus—Eye disorder—Etoposide—testicular cancer	0.00155	0.00238	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00155	0.00237	CcSEcCtD
Pimecrolimus—Diarrhoea—Chlorambucil—testicular cancer	0.00155	0.00237	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—FGFR3—testicular cancer	0.00155	0.007	CbGpPWpGaD
Pimecrolimus—Flushing—Etoposide—testicular cancer	0.00154	0.00236	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vinblastine—testicular cancer	0.00153	0.00234	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Methotrexate—testicular cancer	0.00153	0.00234	CcSEcCtD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KIT—testicular cancer	0.00151	0.00683	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Etoposide—testicular cancer	0.0015	0.0023	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Etoposide—testicular cancer	0.0015	0.0023	CcSEcCtD
Pimecrolimus—Pain—Bleomycin—testicular cancer	0.0015	0.00229	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Ifosfamide—testicular cancer	0.0015	0.00229	CcSEcCtD
Pimecrolimus—Oedema—Ifosfamide—testicular cancer	0.0015	0.00229	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00149	0.00228	CcSEcCtD
Pimecrolimus—Infection—Ifosfamide—testicular cancer	0.00149	0.00228	CcSEcCtD
Pimecrolimus—MTOR—Downstream signal transduction—FGFR3—testicular cancer	0.00148	0.00669	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—FGFR3—testicular cancer	0.00147	0.00665	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Ifosfamide—testicular cancer	0.00147	0.00225	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—FGFR3—testicular cancer	0.00146	0.00662	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—FGFR3—testicular cancer	0.00145	0.00659	CbGpPWpGaD
Pimecrolimus—Skin disorder—Ifosfamide—testicular cancer	0.00145	0.00223	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—H2AFZ—testicular cancer	0.00145	0.00658	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KIT—testicular cancer	0.00144	0.00653	CbGpPWpGaD
Pimecrolimus—Vomiting—Chlorambucil—testicular cancer	0.00144	0.0022	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00143	0.00649	CbGpPWpGaD
Pimecrolimus—Dermatitis exfoliative—Epirubicin—testicular cancer	0.00143	0.00219	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—KIT—testicular cancer	0.00142	0.00643	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Vinblastine—testicular cancer	0.00142	0.00217	CcSEcCtD
Pimecrolimus—Back pain—Etoposide—testicular cancer	0.0014	0.00214	CcSEcCtD
Pimecrolimus—Pain—Dactinomycin—testicular cancer	0.0014	0.00214	CcSEcCtD
Pimecrolimus—Urticaria—Bleomycin—testicular cancer	0.00139	0.00213	CcSEcCtD
Pimecrolimus—Body temperature increased—Bleomycin—testicular cancer	0.00138	0.00212	CcSEcCtD
Pimecrolimus—MTOR—DAP12 interactions—FGFR3—testicular cancer	0.00137	0.0062	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00137	0.0062	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—FGFR3—testicular cancer	0.00137	0.0062	CbGpPWpGaD
Pimecrolimus—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00136	0.00209	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—FGFR3—testicular cancer	0.00136	0.00614	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KIT—testicular cancer	0.00136	0.00614	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KIT—testicular cancer	0.00135	0.00611	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.00134	0.00609	CbGpPWpGaD
Pimecrolimus—Nausea—Chlorambucil—testicular cancer	0.00134	0.00206	CcSEcCtD
Pimecrolimus—Paraesthesia—Ifosfamide—testicular cancer	0.00134	0.00206	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB2—KIT—testicular cancer	0.00134	0.00608	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—FGFR3—testicular cancer	0.00134	0.00606	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.00134	0.00205	CcSEcCtD
Pimecrolimus—MTOR—DAP12 signaling—KIT—testicular cancer	0.00134	0.00605	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00134	0.00204	CcSEcCtD
Pimecrolimus—Dyspnoea—Ifosfamide—testicular cancer	0.00133	0.00204	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—testicular cancer	0.00132	0.00202	CcSEcCtD
Pimecrolimus—Vomiting—Vinblastine—testicular cancer	0.00132	0.00202	CcSEcCtD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00132	0.00596	CbGpPWpGaD
Pimecrolimus—Breast disorder—Methotrexate—testicular cancer	0.0013	0.00199	CcSEcCtD
Pimecrolimus—Face oedema—Epirubicin—testicular cancer	0.0013	0.00199	CcSEcCtD
Pimecrolimus—Headache—Vinblastine—testicular cancer	0.0013	0.00199	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00129	0.00198	CcSEcCtD
Pimecrolimus—Abdominal pain—Dactinomycin—testicular cancer	0.00129	0.00198	CcSEcCtD
Pimecrolimus—Body temperature increased—Dactinomycin—testicular cancer	0.00129	0.00198	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cisplatin—testicular cancer	0.00129	0.00197	CcSEcCtD
Pimecrolimus—Oedema—Cisplatin—testicular cancer	0.00129	0.00197	CcSEcCtD
Pimecrolimus—Hypersensitivity—Bleomycin—testicular cancer	0.00129	0.00197	CcSEcCtD
Pimecrolimus—Infection—Cisplatin—testicular cancer	0.00128	0.00196	CcSEcCtD
Pimecrolimus—Constipation—Ifosfamide—testicular cancer	0.00128	0.00196	CcSEcCtD
Pimecrolimus—Pain—Ifosfamide—testicular cancer	0.00128	0.00196	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—FGFR3—testicular cancer	0.00127	0.00574	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Cisplatin—testicular cancer	0.00127	0.00194	CcSEcCtD
Pimecrolimus—Cough—Etoposide—testicular cancer	0.00126	0.00193	CcSEcCtD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KIT—testicular cancer	0.00126	0.00569	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KIT—testicular cancer	0.00126	0.00569	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00126	0.00569	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KITLG—testicular cancer	0.00125	0.00568	CbGpPWpGaD
Pimecrolimus—Skin disorder—Cisplatin—testicular cancer	0.00125	0.00192	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR—KIT—testicular cancer	0.00125	0.00564	CbGpPWpGaD
Pimecrolimus—Asthma—Methotrexate—testicular cancer	0.00125	0.00191	CcSEcCtD
Pimecrolimus—Pruritus—Bleomycin—testicular cancer	0.00124	0.0019	CcSEcCtD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00123	0.00559	CbGpPWpGaD
Pimecrolimus—Nausea—Vinblastine—testicular cancer	0.00123	0.00189	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Epirubicin—testicular cancer	0.00123	0.00188	CcSEcCtD
Pimecrolimus—MTOR—Signaling by PDGF—KIT—testicular cancer	0.00123	0.00557	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00122	0.00187	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00122	0.00187	CcSEcCtD
Pimecrolimus—Breast disorder—Epirubicin—testicular cancer	0.00122	0.00186	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00121	0.00549	CbGpPWpGaD
Pimecrolimus—Nasopharyngitis—Epirubicin—testicular cancer	0.00121	0.00185	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—testicular cancer	0.0012	0.00184	CcSEcCtD
Pimecrolimus—Hypersensitivity—Dactinomycin—testicular cancer	0.0012	0.00184	CcSEcCtD
Pimecrolimus—Urticaria—Ifosfamide—testicular cancer	0.00119	0.00182	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—BCL10—testicular cancer	0.00119	0.00537	CbGpPWpGaD
Pimecrolimus—Abdominal pain—Ifosfamide—testicular cancer	0.00118	0.00181	CcSEcCtD
Pimecrolimus—Body temperature increased—Ifosfamide—testicular cancer	0.00118	0.00181	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—testicular cancer	0.00118	0.00181	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00118	0.0018	CcSEcCtD
Pimecrolimus—Infection—Etoposide—testicular cancer	0.00117	0.0018	CcSEcCtD
Pimecrolimus—Influenza—Epirubicin—testicular cancer	0.00117	0.00178	CcSEcCtD
Pimecrolimus—Asthma—Epirubicin—testicular cancer	0.00117	0.00178	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—KIT—testicular cancer	0.00116	0.00527	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Cisplatin—testicular cancer	0.00116	0.00177	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—testicular cancer	0.00116	0.00177	CcSEcCtD
Pimecrolimus—Dyspnoea—Cisplatin—testicular cancer	0.00115	0.00176	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—testicular cancer	0.00115	0.00176	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—BCL10—testicular cancer	0.00114	0.00516	CbGpPWpGaD
Pimecrolimus—Abdominal pain upper—Doxorubicin—testicular cancer	0.00114	0.00174	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—testicular cancer	0.00114	0.00174	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—testicular cancer	0.00113	0.00173	CcSEcCtD
Pimecrolimus—Bronchitis—Epirubicin—testicular cancer	0.00112	0.00172	CcSEcCtD
Pimecrolimus—Diarrhoea—Dactinomycin—testicular cancer	0.00112	0.00171	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—testicular cancer	0.00112	0.00171	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—testicular cancer	0.00112	0.00171	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00111	0.0017	CcSEcCtD
Pimecrolimus—Vomiting—Bleomycin—testicular cancer	0.00111	0.0017	CcSEcCtD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00111	0.00504	CbGpPWpGaD
Pimecrolimus—Infestation—Methotrexate—testicular cancer	0.00111	0.0017	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—testicular cancer	0.00111	0.0017	CcSEcCtD
Pimecrolimus—Rash—Bleomycin—testicular cancer	0.0011	0.00169	CcSEcCtD
Pimecrolimus—Pain—Cisplatin—testicular cancer	0.0011	0.00169	CcSEcCtD
Pimecrolimus—Dermatitis—Bleomycin—testicular cancer	0.0011	0.00169	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ifosfamide—testicular cancer	0.0011	0.00169	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Epirubicin—testicular cancer	0.00108	0.00166	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—testicular cancer	0.00108	0.00165	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—testicular cancer	0.00108	0.00165	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—testicular cancer	0.00108	0.00165	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Epirubicin—testicular cancer	0.00106	0.00163	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—testicular cancer	0.00106	0.00162	CcSEcCtD
Pimecrolimus—Pruritus—Ifosfamide—testicular cancer	0.00106	0.00162	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—testicular cancer	0.00105	0.00161	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—testicular cancer	0.00105	0.0016	CcSEcCtD
Pimecrolimus—Pneumonia—Epirubicin—testicular cancer	0.00105	0.0016	CcSEcCtD
Pimecrolimus—Nausea—Bleomycin—testicular cancer	0.00104	0.00159	CcSEcCtD
Pimecrolimus—Infestation—Epirubicin—testicular cancer	0.00104	0.00159	CcSEcCtD
Pimecrolimus—Infestation NOS—Epirubicin—testicular cancer	0.00104	0.00159	CcSEcCtD
Pimecrolimus—Vomiting—Dactinomycin—testicular cancer	0.00104	0.00159	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—testicular cancer	0.00104	0.00159	CcSEcCtD
Pimecrolimus—Rash—Dactinomycin—testicular cancer	0.00103	0.00158	CcSEcCtD
Pimecrolimus—Diarrhoea—Ifosfamide—testicular cancer	0.00102	0.00157	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—testicular cancer	0.00102	0.00156	CcSEcCtD
Pimecrolimus—Body temperature increased—Cisplatin—testicular cancer	0.00102	0.00156	CcSEcCtD
Pimecrolimus—Pain—Etoposide—testicular cancer	0.00101	0.00155	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—testicular cancer	0.00101	0.00155	CcSEcCtD
Pimecrolimus—Conjunctivitis—Epirubicin—testicular cancer	0.00101	0.00155	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.001	0.00153	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—testicular cancer	0.000989	0.00151	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000984	0.00151	CcSEcCtD
Pimecrolimus—Epistaxis—Epirubicin—testicular cancer	0.00098	0.0015	CcSEcCtD
Pimecrolimus—Sinusitis—Epirubicin—testicular cancer	0.000975	0.00149	CcSEcCtD
Pimecrolimus—Nausea—Dactinomycin—testicular cancer	0.00097	0.00148	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—testicular cancer	0.000967	0.00148	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—testicular cancer	0.000967	0.00148	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—testicular cancer	0.000961	0.00147	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—testicular cancer	0.000961	0.00147	CcSEcCtD
Pimecrolimus—Vomiting—Ifosfamide—testicular cancer	0.000952	0.00146	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cisplatin—testicular cancer	0.000951	0.00146	CcSEcCtD
Pimecrolimus—Rash—Ifosfamide—testicular cancer	0.000944	0.00144	CcSEcCtD
Pimecrolimus—Dermatitis—Ifosfamide—testicular cancer	0.000943	0.00144	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—testicular cancer	0.000939	0.00144	CcSEcCtD
Pimecrolimus—Rhinitis—Epirubicin—testicular cancer	0.000935	0.00143	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—testicular cancer	0.000935	0.00143	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—testicular cancer	0.000935	0.00143	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—testicular cancer	0.000934	0.00143	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—FGFR3—testicular cancer	0.000932	0.00422	CbGpPWpGaD
Pimecrolimus—Eye disorder—Methotrexate—testicular cancer	0.000931	0.00143	CcSEcCtD
Pimecrolimus—Pharyngitis—Epirubicin—testicular cancer	0.000926	0.00142	CcSEcCtD
Pimecrolimus—MTOR—Signaling Pathways—INSL3—testicular cancer	0.000915	0.00414	CbGpPWpGaD
Pimecrolimus—Epistaxis—Doxorubicin—testicular cancer	0.000907	0.00139	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—testicular cancer	0.000902	0.00138	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—testicular cancer	0.0009	0.00138	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—testicular cancer	0.000898	0.00137	CcSEcCtD
Pimecrolimus—Nausea—Ifosfamide—testicular cancer	0.000889	0.00136	CcSEcCtD
Pimecrolimus—Diarrhoea—Cisplatin—testicular cancer	0.000883	0.00135	CcSEcCtD
Pimecrolimus—Eye disorder—Epirubicin—testicular cancer	0.000872	0.00133	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—testicular cancer	0.000871	0.00133	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—testicular cancer	0.000868	0.00133	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—testicular cancer	0.000868	0.00133	CcSEcCtD
Pimecrolimus—Flushing—Epirubicin—testicular cancer	0.000866	0.00132	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—testicular cancer	0.000865	0.00132	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—testicular cancer	0.000857	0.00131	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—KIT—testicular cancer	0.000856	0.00388	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Epirubicin—testicular cancer	0.000842	0.00129	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Epirubicin—testicular cancer	0.000841	0.00129	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—testicular cancer	0.000839	0.00128	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—testicular cancer	0.000836	0.00128	CcSEcCtD
Pimecrolimus—Vomiting—Cisplatin—testicular cancer	0.00082	0.00126	CcSEcCtD
Pimecrolimus—Rash—Cisplatin—testicular cancer	0.000814	0.00125	CcSEcCtD
Pimecrolimus—Dermatitis—Cisplatin—testicular cancer	0.000813	0.00124	CcSEcCtD
Pimecrolimus—Erythema—Epirubicin—testicular cancer	0.000812	0.00124	CcSEcCtD
Pimecrolimus—Malnutrition—Epirubicin—testicular cancer	0.000812	0.00124	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—testicular cancer	0.000809	0.00124	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—testicular cancer	0.000807	0.00123	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—testicular cancer	0.000801	0.00123	CcSEcCtD
Pimecrolimus—Back pain—Epirubicin—testicular cancer	0.000785	0.0012	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—testicular cancer	0.00078	0.00119	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—testicular cancer	0.000778	0.00119	CcSEcCtD
Pimecrolimus—Nausea—Cisplatin—testicular cancer	0.000766	0.00117	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—testicular cancer	0.000757	0.00116	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—testicular cancer	0.000752	0.00115	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—testicular cancer	0.000751	0.00115	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—testicular cancer	0.000751	0.00115	CcSEcCtD
Pimecrolimus—Rash—Etoposide—testicular cancer	0.000745	0.00114	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—testicular cancer	0.000745	0.00114	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—H2AFZ—testicular cancer	0.000744	0.00337	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000743	0.00337	CbGpPWpGaD
Pimecrolimus—Headache—Etoposide—testicular cancer	0.000741	0.00113	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—testicular cancer	0.000739	0.00113	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000734	0.00112	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—testicular cancer	0.000727	0.00111	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—KITLG—testicular cancer	0.000716	0.00324	CbGpPWpGaD
Pimecrolimus—Cough—Epirubicin—testicular cancer	0.000709	0.00108	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—testicular cancer	0.000708	0.00108	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—testicular cancer	0.000703	0.00108	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—testicular cancer	0.000702	0.00107	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—testicular cancer	0.000694	0.00106	CcSEcCtD
Pimecrolimus—Arthralgia—Epirubicin—testicular cancer	0.000691	0.00106	CcSEcCtD
Pimecrolimus—MTOR—Immune System—BCL10—testicular cancer	0.000691	0.00313	CbGpPWpGaD
Pimecrolimus—Skin disorder—Methotrexate—testicular cancer	0.000688	0.00105	CcSEcCtD
Pimecrolimus—MTOR—Adaptive Immune System—KITLG—testicular cancer	0.000687	0.00311	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000686	0.00105	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—KITLG—testicular cancer	0.000684	0.0031	CbGpPWpGaD
Pimecrolimus—Oedema—Epirubicin—testicular cancer	0.000663	0.00101	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Epirubicin—testicular cancer	0.000663	0.00101	CcSEcCtD
Pimecrolimus—Infection—Epirubicin—testicular cancer	0.000658	0.00101	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—testicular cancer	0.000656	0.001	CcSEcCtD
Pimecrolimus—Nervous system disorder—Epirubicin—testicular cancer	0.00065	0.000995	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000645	0.000987	CcSEcCtD
Pimecrolimus—Skin disorder—Epirubicin—testicular cancer	0.000644	0.000985	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—testicular cancer	0.00064	0.000979	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—testicular cancer	0.000636	0.000973	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000635	0.000972	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—testicular cancer	0.000631	0.000966	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—testicular cancer	0.000613	0.000938	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—testicular cancer	0.000613	0.000938	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000611	0.000936	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—testicular cancer	0.000609	0.000932	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—testicular cancer	0.000606	0.000927	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000604	0.000924	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—testicular cancer	0.000601	0.00092	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—testicular cancer	0.000596	0.000911	CcSEcCtD
Pimecrolimus—Paraesthesia—Epirubicin—testicular cancer	0.000595	0.000911	CcSEcCtD
Pimecrolimus—Dyspnoea—Epirubicin—testicular cancer	0.000591	0.000904	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—testicular cancer	0.000579	0.000886	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000572	0.000876	CcSEcCtD
Pimecrolimus—Constipation—Epirubicin—testicular cancer	0.000567	0.000867	CcSEcCtD
Pimecrolimus—Pain—Epirubicin—testicular cancer	0.000567	0.000867	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—testicular cancer	0.000563	0.000861	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—testicular cancer	0.00056	0.000857	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—testicular cancer	0.00056	0.000857	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000559	0.000855	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—testicular cancer	0.000551	0.000843	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—testicular cancer	0.000547	0.000837	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Epirubicin—testicular cancer	0.000542	0.000829	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—FGFR3—testicular cancer	0.000532	0.00241	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000529	0.00081	CcSEcCtD
Pimecrolimus—Urticaria—Epirubicin—testicular cancer	0.000526	0.000806	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—testicular cancer	0.000524	0.000802	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—testicular cancer	0.000524	0.000802	CcSEcCtD
Pimecrolimus—Abdominal pain—Epirubicin—testicular cancer	0.000524	0.000802	CcSEcCtD
Pimecrolimus—Body temperature increased—Epirubicin—testicular cancer	0.000524	0.000802	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—testicular cancer	0.000522	0.000798	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—H2AFZ—testicular cancer	0.000521	0.00236	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STK11—testicular cancer	0.000518	0.00234	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—FGFR3—testicular cancer	0.000511	0.00231	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—FGFR3—testicular cancer	0.000508	0.0023	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000501	0.000767	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—testicular cancer	0.000501	0.000767	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—KIT—testicular cancer	0.000488	0.00221	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Epirubicin—testicular cancer	0.000488	0.000747	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—testicular cancer	0.000487	0.000745	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—testicular cancer	0.000485	0.000742	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—testicular cancer	0.000485	0.000742	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—testicular cancer	0.000484	0.000741	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—KITLG—testicular cancer	0.000479	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KIT—testicular cancer	0.000469	0.00212	CbGpPWpGaD
Pimecrolimus—Pruritus—Epirubicin—testicular cancer	0.000469	0.000718	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—KIT—testicular cancer	0.000467	0.00211	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Epirubicin—testicular cancer	0.000453	0.000694	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—testicular cancer	0.000452	0.000691	CcSEcCtD
Pimecrolimus—Vomiting—Methotrexate—testicular cancer	0.00045	0.000689	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—testicular cancer	0.000446	0.000683	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—testicular cancer	0.000446	0.000683	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—testicular cancer	0.000444	0.000679	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—testicular cancer	0.000434	0.000664	CcSEcCtD
Pimecrolimus—Vomiting—Epirubicin—testicular cancer	0.000421	0.000645	CcSEcCtD
Pimecrolimus—Nausea—Methotrexate—testicular cancer	0.000421	0.000644	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—testicular cancer	0.00042	0.000642	CcSEcCtD
Pimecrolimus—MTOR—Disease—H2AFZ—testicular cancer	0.000418	0.00189	CbGpPWpGaD
Pimecrolimus—Rash—Epirubicin—testicular cancer	0.000418	0.000639	CcSEcCtD
Pimecrolimus—Dermatitis—Epirubicin—testicular cancer	0.000417	0.000639	CcSEcCtD
Pimecrolimus—MTOR—Immune System—KITLG—testicular cancer	0.000417	0.00189	CbGpPWpGaD
Pimecrolimus—Headache—Epirubicin—testicular cancer	0.000415	0.000635	CcSEcCtD
Pimecrolimus—Nausea—Epirubicin—testicular cancer	0.000394	0.000602	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—testicular cancer	0.00039	0.000597	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—testicular cancer	0.000387	0.000592	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—testicular cancer	0.000386	0.000591	CcSEcCtD
Pimecrolimus—MTOR—Disease—KITLG—testicular cancer	0.000385	0.00174	CbGpPWpGaD
Pimecrolimus—Headache—Doxorubicin—testicular cancer	0.000384	0.000588	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—testicular cancer	0.000364	0.000557	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—FGFR3—testicular cancer	0.000356	0.00161	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—testicular cancer	0.000327	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR3—testicular cancer	0.00031	0.0014	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—H2AFZ—testicular cancer	0.000293	0.00133	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STK11—testicular cancer	0.000291	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR3—testicular cancer	0.000286	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—testicular cancer	0.000284	0.00129	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KITLG—testicular cancer	0.000269	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—testicular cancer	0.000263	0.00119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR3—testicular cancer	0.0002	0.000907	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—testicular cancer	0.000184	0.000833	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—testicular cancer	0.000127	0.000576	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—testicular cancer	9.24e-05	0.000418	CbGpPWpGaD
